

Collaborative Working Project Executive Summary

Cardiff and Vale University Health Board: Deliver Solutions for Haematology SACT Capacity Challenges in University Hospital Wales.

Project Title:

A Collaborative Working Agreement between Cardiff and Vale University Health Board and Janssen-Cilag Ltd, a Johnson and Johnson company, to deliver solutions for Haematology SACT capacity challenges in University Hospital Wales.

Partner Organisations:

Cardiff and Vale University Health Board, University Hospital Wales, Heath Park, Cardiff CF14 4XW.

Janssen-Cilag Limited, a Johnson and Johnson company, 50-100 Holmers Farm Way, High Wycombe HP12 4EG

Project Rationale:

There is a need to enable providers across Cardiff and Vale University Health Board to redesign their Multiple Myeloma services across the health boards footprint, to identify alternative treatment delivery options for geographical and/or specific patient cohorts. This will increase clinic efficiency and therefore capacity to deliver patient care, reduce patient travel burden and deliver services closer to home. This will result in reduced delay and non-attendance at clinics, as well as increase capacity to new diagnosed patients and introduce other treatment options.

This aligns fully with the Health Board Vision - By 2035 we will be using real time integrated data to inform joint decision making and multi-disciplinary team working, giving people access to and ownership of their data to enable them to manage their health and wellbeing. We will be well on our journey to provide care in the right place, in facilities that are fit for purpose, flexible and promote recovery.”

This collaborative project will map all MM patient’s home location vs their treatment location vs their treatment modality delivered. The data gathered will enable the Health Board to redesign their services across the region, to deliver services closer to patients’ homes, thereby increasing efficiency of outpatient services, reduce delays, optimise trust workforce, and minimise patient travel.

Project Period:

July 2025 – December 2025.

Revised Project Period: Oct 25 - Oct 2026

Benefits:**Patient Specific:**

Provision of treatment and other services that are delivered in a location that minimises the cost and time of travel, reduces waiting time in hospital and rescheduled appointments.

NHS Specific:

Optimise capacity at Health Board treatment centres and build new capacity through alternative patient-centred service provision, improve the patient journey and segmentation, and optimise flow and the delivery of therapies and workforce optimisation. This will deliver improved patient experience and through improved access to innovative therapies which can enhance patient outcomes.

Janssen-Cilag Ltd, a Johnson and Johnson company specific:

Produce an example of a successful collaboration with NHS Wales. which can be used as a case study to be utilised with other NHS organisations, to develop and scale solutions to similar challenges. Allow the therapeutic landscape to evolve for current and future indications for both haematological and solid tumour therapies.

Resource allocation

Johnson & Johnson will provide £22,000 to fund the additional IT solution, enabling data to be gathered and mapped. In addition, 102 hours of Johnson & Johnson colleagues' time will be provided to support the project through all stages of delivery from planning to evaluation.

Cardiff & Vale University Health Board will provide 189 hours of time to the project.

Contact Details

Janssen-Cilag Limited, a Johnson and Johnson company: Amy Grey, Business Unit Director

Cardiff and Vale University Health Board: Dr Ceri Bygrave, Myeloma and Haematology Lead